• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

精神分裂症患者的药物依从性:患者观点及帕利哌酮缓释片的临床应用价值

Medication adherence in schizophrenia: patient perspectives and the clinical utility of paliperidone ER.

作者信息

Birnbaum Michael, Sharif Zafar

机构信息

St. Luke's-Roosevelt Hospital Center, 1111 Amsterdam Ave, New York, NY, USA;

出版信息

Patient Prefer Adherence. 2008 Feb 2;2:233-40. doi: 10.2147/ppa.s3346.

DOI:10.2147/ppa.s3346
PMID:19920968
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2770423/
Abstract

Antipsychotic medications provide the foundation for treatment of acute exacerbations as well as relapse prevention in patients with schizophrenia as demonstrated by rigorous placebo-controlled trials. However, despite their proven effectiveness, poor adherence to prescribed antipsychotic regimens remains the most important driver of suboptimal clinical outcomes in this population. This paper reviews the magnitude of the problem of medication non-adherence in patients with schizophrenia and the various factors that contribute to non-adherence, with particular emphasis on factors related to antipsychotic medications. The profile of the latest atypical antipsychotic, paliperidone extended-release (ER) tablets, is then reviewed and the implications of its unique pharmacokinetic profile for adherence in this patient population are discussed.

摘要

抗精神病药物为精神分裂症患者急性发作的治疗以及复发预防提供了基础,这已被严格的安慰剂对照试验所证实。然而,尽管其疗效已得到证实,但对规定的抗精神病治疗方案依从性差仍然是该人群临床效果欠佳的最重要原因。本文回顾了精神分裂症患者药物不依从问题的严重程度以及导致不依从的各种因素,特别强调了与抗精神病药物相关的因素。随后,对最新的非典型抗精神病药物帕利哌酮缓释片的情况进行了回顾,并讨论了其独特的药代动力学特征对该患者群体依从性的影响。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e114/2770423/c0fb9a883706/ppa-2-233f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e114/2770423/c0fb9a883706/ppa-2-233f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e114/2770423/c0fb9a883706/ppa-2-233f1.jpg

相似文献

1
Medication adherence in schizophrenia: patient perspectives and the clinical utility of paliperidone ER.精神分裂症患者的药物依从性:患者观点及帕利哌酮缓释片的临床应用价值
Patient Prefer Adherence. 2008 Feb 2;2:233-40. doi: 10.2147/ppa.s3346.
2
Paliperidone extended-release tablets for the acute and maintenance treatment of schizophrenia.帕利哌酮缓释片用于精神分裂症的急性和维持治疗。
Clin Ther. 2008 Feb;30(2):231-48. doi: 10.1016/j.clinthera.2008.02.011.
3
Impact of paliperidone palmitate one-month formulation on relapse prevention in patients with schizophrenia: A post-hoc analysis of a one-year, open-label study stratified by medication adherence.棕榈酸帕利哌酮单月制剂对精神分裂症患者复发预防的影响:一项为期一年、开放性研究的事后分析,按药物依从性分层。
J Psychopharmacol. 2018 Jun;32(6):691-701. doi: 10.1177/0269881118772449. Epub 2018 May 16.
4
Dosing and switching of paliperidone ER in patients with schizophrenia: recommendations for clinical practice.帕利哌酮长效注射剂在精神分裂症患者中的剂量调整和转换:临床实践建议。
Ann Gen Psychiatry. 2014 Apr 1;13(1):10. doi: 10.1186/1744-859X-13-10.
5
Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets.用个人和社会表现量表测量处于精神分裂症急性期患者的社会功能:帕利哌酮缓释片三项 III 期临床试验汇总分析结果的解读。
Clin Ther. 2010 Feb;32(2):275-92. doi: 10.1016/j.clinthera.2010.02.003.
6
Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial.用帕利哌酮缓释片治疗精神分裂症:一项为期6周的安慰剂对照试验。
Schizophr Res. 2007 Feb;90(1-3):147-61. doi: 10.1016/j.schres.2006.09.012. Epub 2006 Nov 7.
7
Paliperidone extended release: a review of its use in the management of schizophrenia.帕利哌酮长效制剂:在精神分裂症治疗中的应用评价。
Drugs. 2010 Jul 9;70(10):1295-317. doi: 10.2165/11204840-000000000-00000.
8
Extended-release paliperidone: efficacy, safety and tolerability profile of a new atypical antipsychotic.缓释帕利哌酮:一种新型非典型抗精神病药物的疗效、安全性和耐受性概况
Drugs Today (Barc). 2007 Apr;43(4):249-58. doi: 10.1358/dot.2007.43.4.1067342.
9
Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study.帕利哌酮缓释片(帕利哌酮ER)的疗效、安全性及早期反应:一项为期6周的随机、安慰剂对照研究结果
Schizophr Res. 2007 Jul;93(1-3):117-30. doi: 10.1016/j.schres.2007.03.003. Epub 2007 Apr 26.
10
Efficacy and tolerability of paliperidone ER and other oral atypical antipsychotics in schizophrenia.帕利哌酮缓释片与其他口服非典型抗精神病药物治疗精神分裂症的疗效及耐受性
Int J Clin Pharmacol Ther. 2010 Jun;48(6):383-99. doi: 10.5414/cpp48383.

引用本文的文献

1
Unidentified genotype does not affect pharmacological treatment for patients with first episode psychosis.基因型不明并不影响首发精神分裂症患者的药物治疗。
J Psychopharmacol. 2024 Dec;38(12):1111-1121. doi: 10.1177/02698811241279022. Epub 2024 Sep 29.
2
Antipsychotic medication non-adherence and factors associated among patients with schizophrenia in eastern Ethiopia.抗精神病药物不依从与埃塞俄比亚东部精神分裂症患者相关的因素。
BMC Psychiatry. 2024 Feb 7;24(1):108. doi: 10.1186/s12888-024-05554-0.
3
Patient and Healthcare Professional Preferences for Characteristics of Long-Acting Injectable Antipsychotic Agents for the Treatment of Schizophrenia.

本文引用的文献

1
Psychoeducation and compliance in the treatment of patients with schizophrenia.
Coll Antropol. 2007 Dec;31(4):1111-5.
2
Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study.帕利哌酮缓释片的疗效与安全性:一项为期6周的随机、安慰剂对照研究结果
Biol Psychiatry. 2007 Dec 15;62(12):1363-70. doi: 10.1016/j.biopsych.2007.01.017. Epub 2007 Jun 28.
3
Validity of electronically monitored medication adherence and conventional adherence measures in schizophrenia.精神分裂症中电子监测药物依从性和传统依从性测量方法的有效性
患者和医疗保健专业人员对长效注射抗精神病药物治疗精神分裂症的特征的偏好。
Adv Ther. 2023 May;40(5):2249-2264. doi: 10.1007/s12325-023-02455-8. Epub 2023 Mar 11.
4
Adherence, Healthcare Resource Utilization, and Costs in Medicaid Beneficiaries with Schizophrenia Transitioning from Once-Monthly to Once-Every-3-Months Paliperidone Palmitate.患有精神分裂症的医疗补助受益人群从每月一次帕利哌酮棕榈酸酯注射剂转换为每三个月一次注射剂后的依从性、医疗资源利用及成本情况
Pharmacoecon Open. 2019 Jun;3(2):177-188. doi: 10.1007/s41669-018-0089-9.
5
Initial Clinical Experience of RP5063 Following Single Doses in Normal Healthy Volunteers and Multiple Doses in Patients with Stable Schizophrenia.健康志愿者单次给药和稳定精神分裂症患者多次给药后 RP5063 的初步临床经验。
Clin Transl Sci. 2018 Jul;11(4):387-396. doi: 10.1111/cts.12545. Epub 2018 Apr 10.
6
Patterns of Prescription of Psychotropic Medications and Their Adherence among Patients with Schizophrenia in Two Psychiatric Hospitals in Accra, Ghana: A Cross-Sectional Survey.加纳阿克拉两家精神病院精神分裂症患者精神药物的处方模式及其依从性:一项横断面调查
Psychiatry J. 2018 Jan 1;2018:9850594. doi: 10.1155/2018/9850594. eCollection 2018.
7
Evaluation of sleep profile in schizophrenia patients treated with extended-release paliperidone: an open-label prospective study in Southeast Asia.使用缓释帕利哌酮治疗的精神分裂症患者睡眠状况评估:一项在东南亚开展的开放标签前瞻性研究。
Psychol Res Behav Manag. 2017 Oct 27;10:323-327. doi: 10.2147/PRBM.S132272. eCollection 2017.
8
Pharmacokinetics of RP5063 Following Single Doses to Normal Healthy Volunteers and Multiple Doses Over 10 Days to Stable Schizophrenic Patients.健康志愿者单次给药及稳定精神分裂症患者连续 10 天多次给药后 RP5063 的药代动力学。
Clin Transl Sci. 2018 Jul;11(4):378-386. doi: 10.1111/cts.12518. Epub 2017 Nov 8.
9
Factors associated with medication adherence among patients with schizophrenia in Mekelle, Northern Ethiopia.埃塞俄比亚北部默克莱地区精神分裂症患者药物依从性的相关因素。
PLoS One. 2015 Mar 27;10(3):e0120560. doi: 10.1371/journal.pone.0120560. eCollection 2015.
10
Adherence to oral second-generation antipsychotic medications in patients with schizophrenia and bipolar disorder: physicians' perceptions of adherence vs. pharmacy claims.精神分裂症和双相情感障碍患者口服第二代抗精神病药物的依从性:医生对依从性与药房报销的看法。
Int J Clin Pract. 2012 Jun;66(6):565-73. doi: 10.1111/j.1742-1241.2012.02918.x. Epub 2012 May 11.
Psychiatr Serv. 2007 Jun;58(6):844-7. doi: 10.1176/ps.2007.58.6.844.
4
Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study.帕利哌酮缓释片(帕利哌酮ER)的疗效、安全性及早期反应:一项为期6周的随机、安慰剂对照研究结果
Schizophr Res. 2007 Jul;93(1-3):117-30. doi: 10.1016/j.schres.2007.03.003. Epub 2007 Apr 26.
5
Differential medication adherence among patients with schizophrenia and comorbid diabetes and hypertension.精神分裂症合并糖尿病和高血压患者的药物依从性差异
Psychiatr Serv. 2007 Feb;58(2):207-12. doi: 10.1176/ps.2007.58.2.207.
6
Lack of insight in schizophrenia: impact on treatment adherence.精神分裂症中的自知力缺失:对治疗依从性的影响。
CNS Drugs. 2007;21(2):129-41. doi: 10.2165/00023210-200721020-00004.
7
Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial.用帕利哌酮缓释片治疗精神分裂症:一项为期6周的安慰剂对照试验。
Schizophr Res. 2007 Feb;90(1-3):147-61. doi: 10.1016/j.schres.2006.09.012. Epub 2006 Nov 7.
8
Optimizing adherence to treatment in patients with schizophrenia.优化精神分裂症患者的治疗依从性。
Behav Healthc. 2006 Aug;26(8):38-42.
9
Defining and assessing adherence to oral antipsychotics: a review of the literature.定义和评估口服抗精神病药物的依从性:文献综述
Schizophr Bull. 2006 Oct;32(4):724-42. doi: 10.1093/schbul/sbj075. Epub 2006 May 17.
10
Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care.常规治疗中精神分裂症治疗的药物依从性和长期功能结局
J Clin Psychiatry. 2006 Mar;67(3):453-60. doi: 10.4088/jcp.v67n0317.